Is Institutional Interest in Pfizer (NYSE:PFE) Growing?

2 min read | February 10, 2025 03:04 AM PST | By Team Kalkine Media

Is Institutional Interest in Pfizer (NYSE:PFE) Growing? — Image source: Shutterstock

WCM Investment Management Expands Holdings

WCM Investment Management LLC significantly increased its position in Pfizer during the fourth quarter, according to the latest filing with the Securities and Exchange Commission. The firm expanded its stake by 128.7%, acquiring an additional 65,238 shares and bringing its total holdings to 115,913 shares. As of the most recent filing, the firm’s stake in Pfizer was valued at approximately $3,062,000.

Other Institutional Investors Adjust Positions

Several large institutional firms also modified their holdings in Pfizer in recent quarters. Charles Schwab Investment Management Inc. raised its stake by 11.0% in the third quarter, adding 12,864,343 shares. The firm now holds 130,143,942 shares, valued at approximately $3,766,366,000.

UBS AM, a distinct unit of UBS Asset Management Americas LLC, saw a 22.4% increase in its Pfizer holdings during the same period. The firm added 6,977,587 shares, bringing its total to 38,068,879 shares, valued at approximately $1,101,713,000.

New Acquisitions and Expansions

International Assets Investment Management LLC entered a new position in Pfizer during the third quarter, with an acquisition valued at approximately $146,481,000. Meanwhile, BNP Paribas Asset Management Holding S.A. increased its stake by 164.2%, purchasing an additional 4,546,809 shares, bringing its total to 7,316,405 shares, valued at $211,737,000.

Fisher Asset Management LLC also made significant changes to its Pfizer holdings, boosting its position by 226.7% in the third quarter. The firm acquired an additional 4,309,076 shares, raising its total to 6,209,907 shares, worth approximately $179,715,000.

Institutional Ownership Overview

Institutional investors collectively hold about 68.36% of Pfizer's stock. This level of ownership suggests continued engagement from major financial entities, reflecting shifts in institutional strategies within the biopharmaceutical sector. As more firms adjust their stakes, tracking these changes provides insight into broader trends within the industry.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.